SCHEMBL29408889

SCHEMBL29408889

CC(NC(=O)C12CC(NC(=O)OC(C)(C)C)(C1)C2)C(=O)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ TRPA1 O75762 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ CACNA1B Q00975 1/20 0.36
▸ DRD2 P14416 5/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ ATF4 P18848 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22614248 0.83 RAB9A (0.38) TRPA1ALDH1A1TSHRMEN1KMT2A
SCHEMBL2762834 0.80 TRPA1 (0.52) PPARGPPARATRPA1ALDH1A1MAPT
SCHEMBL29409118 0.79 GAA (0.42) PPARGPPARAALDH1A1MAPTLMNA
SCHEMBL29525089 0.73 DRD2 (0.47) PPARGPPARATRPA1ALDH1A1MAPT
SCHEMBL31501042 0.72 ATF4 (0.57) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL29435970 0.72 DPP9 (0.44) PPARGPPARAALDH1A1MAPTLMNA
SCHEMBL30445754 0.71 GHSR (0.43) ALDH1A1GAADRD2SMN1; SMN2NPSR1
SCHEMBL21504118 0.70 IDO1 (0.60) MAPTLMNAMEN1KMT2A
SCHEMBL21601666 0.69 MEN1 (0.39) TSHRGAAMEN1KMT2A
SCHEMBL21618343 0.69 MEN1 (0.39) GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2025-05-08 — — US disclosed
EP-4237413-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2023-09-06 — — EP disclosed
WO-2022094244-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-05-05 — — WO disclosed
CN-114206848-A Substituted cycloalkyl compounds as modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-03-18 — — CN disclosed
EP-3962906-A1 SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2022-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PPARG 644/4885PPARA 2101/4885TRPA1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback